The phosphatidylinositol 3V-kinase (PI3K) pathway is frequently activated in thyroid carcinomas through the constitutive activation of stimulatory molecules (e.g., Ras) and/or the loss of expression and/or function of the inhibitory PTEN protein that results in Akt activation. Recently, it has been reported that somatic mutations within the PI3K catalytic subunit, PIK3CA, are common (25-40%) among colorectal, gastric, breast, ovarian cancers, and high-grade brain tumors. Moreover, PIK3CA mutations have a tendency to cluster within the helical (exon 9) and the kinase (exon 20) domains. In this study, 13 thyroid cancer cell lines, 80 well-differentiated thyroid carcinomas of follicular (WDFC) and papillary (WDPC) type, and 70 anaplastic thyroid carcinomas (ATC) were investigated, by PCR-direct sequencing, for activating PIK3CA mutations at exons 9 and 20. Nonsynonymous somatic mutations were found in 16 ATC (23%), two WDFC (8%), and one WDPC (2%). In 18 of the 20 ATC cases showing coexisting differentiated carcinoma, mutations, when present, were restricted to the ATC component and located primarily within the kinase domain. Three cell lines of papillary and follicular lineage (K1, K2, and K5) were also found mutated. In addition, activation of Akt was observed in most of the ATC harboring PIK3CA mutations. These findings indicate that mutant PIK3CA is likely to function as an oncogene among ATC and less frequently well-differentiated thyroid carcinomas. The data also argue for a role of PIK3CA targeting in the treatment of ATC patients. (Cancer Res 2005; 65(22): 10199-207) 
Introduction
The PIK3CA gene, located at 3q26, encodes the catalytic subunit p110a of a class IA phosphatidylinositol 3V-kinase (PI3K). PI3K is a component of the PTEN/PI3K/AKT pathway that regulates fundamental cellular processes linked to tumorigenesis, including cell cycle progression, cell survival, adhesion, motility and spreading, angiogenesis, glucose homeostasis, and cell size and organ size control (1, 2) . Available genetic evidences strongly suggest that the PTEN/PI3K/AKT pathway constitutes a pivotal signaling cascade in thyroid carcinogenesis (3) (4) (5) (6) (7) (8) (9) (10) . Signaling through PI3K begins with signals relayed to the internal cellular environment by transmembrane receptor tyrosine kinases (RTK). Upon ligand activation, RTKs engage the p85-regulatory subunit of PI3K that forms a heterodimer with the p110a-catalytic subunit (PIK3CA) leading to the membrane recruitment of PI3K and the generation of phosphatidylinositol-3-4-5-triphosphate (PIP3). Subsequently, PIP3 acts as membraneembedded second messenger that bind the pleckstrin homology domain of two serine/threonine protein kinases, PDK1 and Akt, which colocalize at the membrane. Once in the membrane, Akt is activated, in part through phosphorylation by PDK1, and is then capable of phosphorylating several downstream targets, enhancing cell proliferation and survival (1, 2) . The cell has evolved, however, a mechanism for switching ''off '' the PI3K signaling in both the normal response to growth stimuli and the abnormal response to transforming signals. The PTEN lipid phosphatase, by removing a phosphate group from the inositol ring of PIP3, is responsible for turning ''off '' the PI3K pathway, antagonizing the activity of Akt (1, 2) . In thyroid cancer, it has been shown that PTEN inactivation and Akt activation are associated with tumor progression. PTEN is downregulated or lost among highly malignant or late-stage thyroid cancers as the anaplastic thyroid carcinoma (ATC; >50%; refs. [3] [4] [5] [6] [7] [8] , and Akt activation correlates with regions of tumor invasion and with tumor metastases (9, 10) . Because loss of PTEN function is regarded as a critical step in the progression of thyroid cancer, it is reasonable to hypothesize that PI3K activation through gain-offunction mutations might have similar effects. In fact, four recent studies, focused in establishing if PI3Ks are genetically altered in human cancers, have revealed a high frequency of PIK3CA somatic mutations (25-40%) among colorectal, gastric, breast, ovarian cancer, and high-grade brain tumors, being the majority of the mutants located within the helical (exon 9) and the kinase (exon 20) domains (11) (12) (13) (14) (15) (16) . In the attempt to improve our present knowledge about the PTEN/PI3K/AKT pathway in the development and progression of thyroid cancer, we investigated in this study the existence of PIK3CA mutations in 80 well-differentiated thyroid carcinomas of follicular (WDFC) and papillary (WDPC) type and 70 ATC.
Materials and Methods
Tissue samples and human thyroid cancer cell lines. The study population included 189 tumor specimens, comprising 54 samples of WDPC, 26 samples of WDFC, and 109 samples from 70 ATC patients. In the case of ATC, more than one tumor specimen was analyzed in individual patients: in particular, in 24 ATC concurrent better-differentiated thyroid carcinoma foci, areas with different microscopic appearance (e.g., spindle/sarcomatoid-like or giant cell/epithelioid pattern of growth) but the same histologic grade, recurrences, and/or lymph node metastases were separately genotyped (see Table 1 ). Four random normal thyroids were also recruited into the study. Fifty-two specimens were frozen at the time of surgery and the remaining 141 were formalin fixed and paraffin embedded. Normal thyroid tissue from the same cohort of patients was available in 22 ATC cases, 14 WDFC, and 19 WDPC. Tumors were retrieved from the files of the Pathology Departments at Hospital Universitario Central de Asturias (Spain), Hospital Clinico Universitario de Santiago de Compostela (Spain), and the Dipartimento di Biologia e Patologia Cellulare e Molecolare-Federico II University (Naples, Italy). Patients were chosen randomly among those with detailed clinical and follow-up data. All histologic diagnosis were reviewed according to established histologic criteria (17) . Processing of samples and of patient information proceeded in agreement with review board-approved protocols.
The panel of thyroid cancer cell lines analyzed included six derived from ATC (ARO, 8505C, CAL62, KAT4, FB1, and BHT101), two originated from follicular carcinomas (WRO and K5), one originated from a Hürthle cell variant of follicular carcinoma (XTC-1), and four derived from papillary carcinomas (K1, K2, B-CPAP, and NPA; the latter derived from a poorly differentiated papillary carcinoma).
DNA isolation. Overall, DNA was isolated from 248 tissue samples (189 tumor and 59 nontumoral samples). Whenever necessary, tumor material was microdissected to increase the proportion of cancer cells that always represented at least 80% of the total. Genomic DNA was extracted from tissue samples accordingly to a previously described phenol-chloroform method (18) and from the thyroid cancer cell lines with the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN).
Mutational and sequencing analysis. Mutational analysis was limited to the helical domain encoded by exon 9 and the kinase domain encoded by exon 20 because recent large-scale analyses of PIK3CA mutations in different tumor types revealed that 80% of the mutations clustered within those domains (11, 13) . Genomic DNA was evaluated for the existence of mutations by PCR of the target sequences followed by direct sequencing. Primer pairs flanking PIK3CA exons 9 and 20 were specifically designed to avoid the frequent cross-amplification of chromosome 22q observed with those previously reported. Primer sequences were as follows: exon 9 forward, 5V -ATCATCTGTGAATCCAGA-3V ; exon 9 reverse, 5V -TTAGCACT-TACCTGTGAC-3V ; exon 20 forward, 5V -TGACATTTGAGCAAAGACC-3V ; and exon 20 reverse, 5V -GTGTGGAATCCAGAGTGA-3V . The PCR was carried out in 30 AL of reaction mixture containing 20 to 100 ng of genomic DNA, 0.5 Amol/L of each exon 9 primer, 0.25 Amol/L of each exon 20 primer, 200 Amol/L deoxynucleotide triphosphates, 3 mmol/L MgCl 2 , 1Â buffer/ MgCl 2 free, and 1 unit of DNA polymerase. The mixture was heated for 10 minutes at 95jC for initial target strand dissociation followed by 40 cycles of denaturation (45 seconds at 94jC), annealing (45 seconds at 55jC for exon 9 and 58jC for exon 20) , and extension (45 seconds at 72jC). Yield products were electrophoresed onto 3% agarose gels to verify the adequacy of the PCR reaction and purified using the GFX PCR DNA and gel band purification Kit (Amersham Biosciences, Piscataway, NJ). Direct sequencing was done in a capillary automatic sequencer (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems, Foster City, CA) using the BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems) and the aforementioned primers. Nucleotide sequencing from both the sense and antisense orientation was done for confirmation. All mutated cases were verified by repeated PCR from a new DNA template and sequencing.
Immunohistochemistry for phospho-Akt. A tissue microarray (TMA) of ATC, including 38 of the tumors analyzed for PIK3CA mutations, was used to carry out the immunohistochemical analysis of phospho-Akt. To improve the representativity of the expression analyses, two to six core biopsies of 1 mm in diameter from different regions of the same specimen or different blocks of the tumor were included in the TMA block (192 tissue cores). In addition, whenever observed, within a particular tumor, a concurrent betterdifferentiated component representative tissue cores from that area were also extruded into the recipient TMA block. To ensure the reproducibility of the results, phospho-Akt was evaluated in two consecutive TMA slides. Each section was deparaffinized, soaked in ethanol and, after treatment by immersion in a conventional steamer with antigen unmasking solution [buffer Tris-EDTA (pH 9.0), DAKO, Glostrup, Denmark] at 90jC for 40 minutes, incubated with blocking solution at room temperature. Antiphospho-Akt (Ser 473 ) polyclonal antibody (immunohistochemistry specific; Cell Signaling Technology, Beverly, MA) was then applied to sections at 1:25 dilution. After incubation with the primary antibody, immunodetection was done using a universal secondary antibody kit that incorporates a peroxidaseconjugated labeled dextran polymer (Peroxidase/3,3V -Diaminobenzidine EnVision System for polyclonal antibodies, DAKO). Negative controls by omitting the primary antibody were included in the assay. Immunoreactivity was expressed as the percentage of positively stained target cells in four intensity categories (À, staining; +, low/weak; ++, moderate/distinct; +++, high/intense). The presence or absence of staining was independently estimated by two blinded investigators (G.G.R. and J.C.T.), and a consensus was reached on all values used for computation.
Results
PIK3CA mutations in thyroid carcinomas and human thyroid cancer cell lines. Mutational analysis revealed missense Abbreviation: PDC, poorly differentiated thyroid carcinoma. *n = number of tumors. cThe ATC was genotyped at the lymph node metastasis in two tumors with concurrent areas of WDPC (specimen 216a) or WDFC (specimen 213d) in the primary tumor. bOne of the tumors derived from a previous papillary carcinoma and the other two from a previous follicular carcinoma. x In two of the tumors, the areas with spindle/sarcomatoid-like and giant cell/epithelioid appearance were analyzed at the primary tumor and its recurrence.
mutations in the tumor of 16 ATC patients (23%). The specific nucleotide change and the corresponding amino acid substitution are summarized in Table 2 . Matching nontumoral DNA was available for 9 of the 16 positive ATC samples, and in all nine cases, the mutations were found to be tumor specific. Additional sequencing of four randomly chosen normal thyroids disclosed no mutations at PIK3CA. Among those mutated ATC where no corresponding normal DNA was analyzed, all the alterations, but two (G1007D and T1031I), have been shown to be somatic changes either in a different tumor histotype from this series or in other primary human cancers (11) (12) (13) . The mutational screening of 80 well-differentiated thyroid carcinoma specimens showed missense mutations in 2 of 26 WDFC (8%) and 1 of 54 WDPC (2%; see Table 2 ). The two follicular carcinomas bore alterations that were also identified in the ATC group. The genotyping of nontumoral DNA, in the WDFC exhibiting the G1009E mutant, indicated that was a somatic mutation. Two additional WDFC harbored silent sequence variants (see Table 2 ). The only mutated WDPC displayed a G1633C transversion in exon 9, which was verified to be a somatic change. Nineteen of 21 nucleotide alterations detected in this cohort resulted in nonsynonymous, heterozygous mutations (90.5%). Similarly to colon cancer (11, 13), Lys, E > K 113-114
Gln, E > Q Abbreviations: WT, wild type; MUT, mutated; NT, corresponding nontumoral DNA available for PIK3CA screening; ND, not done. *Exon number with altered nucleotide position and corresponding amino acid substitution. Boldface, mutations not previously reported. cATC (sample 103a) with concurrent foci of poorly differentiated thyroid carcinoma (sample 103b). Both exhibited identical PIK3CA mutation. bATC with a mixed pattern of growth, showing primarily a spindle/sarcomatoid-like microscopic appearance at the primary tumor (specimen 113) and a giant cell/epithelioid appearance in the recurrence (specimen 114). Both displayed identical PIK3CA mutation.
x Not more DNA available. k Codon most commonly targeted in colon and ovarian cancer with amino acid substitution not reported thus far. { WDPC with a mixed pattern of growth, follicular (sample 20a) and papillary (sample 20b) that had concurrent lymph node metastasis (sample 20c). Identical PIK3CA mutation was present in samples 20a and 20c. All three areas were mutated at BRAF [V600E] and WT at Ras. **ATC genotyped at the lymph node metastasis. The coexistent WDPC and poorly differentiated carcinoma components in the primary tumor were wild type. ccATC (sample 230a) with concurrent foci of well-differentiated papillary carcinoma (sample 230b). Both harbored identical PIK3CA mutation. bbSynonymous mutations. xx WDFC with Hürthle features in which two areas with different microscopic appearance (samples 5b and 5c) and a small foci of progression towards poorly differentiated carcinoma (sample 5a) were analyzed. All three samples disclosed identical PIK3CA mutation.
the proportion between transitions and transversions was 4:1. Transitions were present in 17 (81%) tumors, whereas transversions were observed only in four (19%). The most frequent type of alteration was the G:C > A:T transition at the first or the second nucleotide position of the altered codon, which was found in eight tumors (38% (14, 15) , were all seen in this study (11 cases, 52%). The remaining 10 tumors (48%) harbored mutations at codons, not previously described to be altered, either adjacent or within a few residues of amino acids shown to be mutated in different human cancers (11) (12) (13) (14) (15) (16) . Moreover, the mutations affecting exon 20 showed some tendency to cluster within certain stretches of the coding sequence (1007-1011, 1025-1031, and 1041-1049).
Simultaneous characterization of PIK3CA on 13 thyroid cancer cell lines, originated in different tumor histotypes, evidenced the same amino acid substitution, E542K, in three cell lines (K1, K2, and K5; Fig. 1 ). This mutant has been involved in the oncogenic transformation of chicken embryo fibroblast through deregulated activation of the Akt/mammalian target of Rapamycin (mTOR) pathway (19) . All the other cell lines resulted wild type. Of note, K1 and K2 but not K5 were found to harbor the V600E mutation at the BRAF activation loop, typical of WDPC.
PIK3CA mutations and clinicopathologic features in anaplastic carcinomas. Among the 16 ATC bearing missense mutations, four (25%) originated in a previous WDPC, two (12.5%) originated in a WDFC with oncocytic features, and the remaining 10 (62.5%) did not show any cytologic/architectural feature of papillary or follicular carcinoma derivation. Phenotypically, most of the mutated ATC (13 of 16, 81%) displayed a giant cell/epithelioid morphology with an extremely high degree of pleomorphism, high mitotic activity, and ample areas of necrosis sometimes resembling those seen in glioblastoma multiforme (a high-grade brain tumor recently found mutated at PIK3CA; refs. 11, 12). Figure 2 illustrates some of the ATC that arose mutated in this study.
In all the ATC in which coexisted a better-differentiated carcinoma component (20 cases; Table 1 ), mutational analysis was done in multiple samples microdissected from the same tumor, its recurrence or the local metastasis. In two cases, the concurrent better-differentiated thyroid carcinoma component exhibited identical PIK3CA alteration to that seen in the ATC [WDPC (specimen 230b) associated with ATC (specimen 230a) and PDC (specimen 103b) associated with ATC (specimen 103a)]. In the remaining 18 cases, PIK3CA mutations, when present, were exclusively observed in the ATC component. This finding is consistent with previous reports in which PIK3CA mutations were found in the latest stages of glioma and colon cancer progression (11, 12) and suggest that, in some cases, oncogenic activation of PIK3CA in thyroid cancer may foster the development of more aggressive tumor clones. The low frequency of nonsynonymous mutations detected in WDFC (8%) and WDPC (2%) seems to support this hypothesis. On the other hand, the analysis of multiple areas with different microscopic appearance (e.g., spindle/ sarcomatoid-like or giant cell/epithelioid morphology), but the same histologic grade within the same tumor (e.g., samples 113 and 114; samples 120 and 121) showed that PIK3CA mutations may be focal (e.g., samples 120 and 121, from the same tumor, showed a different PIK3CA status; whereas sample 120 bore a E982K mutation, sample 121 was wild type). This further suggests that ATC exhibit clonal heterogeneity and that at least in some patients, PIK3CA mutations may occur at some late points of tumor progression. The detection within a lymph node colonized by ATC cells (specimen 216a) of a P1011S mutation that was absent in the WDPC component (specimen 216c) and the PDC component (specimen 216b), constitutes another example in favor of a putative involvement of PIK3CA mutations in the development of more aggressive tumor clones and the regulation of thyroid cancer cell invasiveness.
Within the ATC group, in 56 patients, it was known the existence of vascular invasion (86%, 48 cases), extrathyroidal extension (98%, 55 cases), spread of tumor cells (70%, 39 cases), lymph node metastases (46%, 26 cases), and distant metastases (41%, 23 cases) at diagnosis. Although the 16 PIK3CA -mutated ATC were commonly associated with vascular invasion (81%, 13 cases), extrathyroidal extension (100%, all 16 cases), spread of tumor cells (62.5%, 10 cases), lymph node metastases (50%, eight cases), and distant metastases (37.5%, six cases) at diagnosis, the correlation between PIK3CA mutations and all the unfavorable clinicopathologic variables listed above did not reach statistical significance due to the uniformly poor prognosis of ATC in this series. However, the comparison of PIK3CA mutations with clinicopathologic variables in all the thyroid carcinoma patients (ATC, WDFC, and WDPC), for which it was recorded that information, showed that missense PIK3CA mutations were more frequent among males (P = 0.28, Fisher's exact test) and were significantly correlated with age z58 years old (P = 0.028, Fisher's exact test) and extrathyroidal extension (P = 0.020, Fisher's exact test). No attempt was made to correlate PIK3CA mutations with patient survival, because all the ATC patients in this series died within 1 year of the diagnosis.
PIK3CA mutations and clinicopathologic features of welldifferentiated carcinomas. On microscopic examination, one of the two WDFC bearing missense, somatic mutations was a widely invasive tumor (one of three studied, 33%). The other positive WDFC was a minimally invasive tumor (1 of 10 studied, 10%; see Fig. 2 ). Of Figure 1 . Sequence chromatogram from the thyroid cancer cell lines mutated a PIK3CA in this study. All three cell lines harbored identical G:C > A:T transition at the first nucleotide position of codon 542, leading to the replacement of glutamic acid by lysine. A, antisense sequence trace from the K1 thyroid cell line derived from a papillary carcinoma. B, sense sequence trace from the K2 thyroid cell line derived from a papillary carcinoma. C, sense sequence trace from the K5 thyroid cell line derived from a follicular carcinoma. Arrows, altered nucleotide and the corresponding substitution. Brackets encircled the mutated codon.
note, this was the only minimally invasive WDFC that behaved aggressively, developing distant metastases 17 months after surgery and killing the patient in 57 months from diagnosis. This minimally invasive WDFC disclosed the H1047R mutation, the most commonly targeted residue at the kinase domain of PIK3CA in different tumor types with demonstrated oncogenic-transforming activity (19) .
The WDPC mutated at PIK3CA, despite being only 4 cm in diameter, was a highly infiltrative tumor that by the time of diagnosis had invaded the trachea and the esophagus. Indeed, it was the only WDPC that behaved very aggressively killing the patient in 1 month from diagnosis. Phenotypically, it displayed a mixed pattern of growth, with areas showing the classic papillary architecture intermingled with areas exhibiting a follicular pattern of growth. Of note, the E545Q amino acid substitution, which represents the most frequently mutated residue of PIK3CA in ovarian (15) and colon cancer (11), was only observed in the area with a follicular pattern of growth. Identical mutation arose in the lymph node metastasis analyzed from that patient.
Fourteen of 19 (74%) patients diagnosed of WDFC and 18 of 21 (86%) patients diagnosed of WDPC, with available follow-up data, were alive without any evidence of disease after an average followup period of 6 years on each group. Five WDFC patients (26%), including those whose tumors harbored PIK3CA missense mutations, developed lung and/or bone metastases between 2 and 26 months from diagnosis, dying of disease in 3 years of average follow-up. Three WDPC patients (14%), including the only one whose tumor resulted PIK3CA positive, died of disease in 2 years of average follow-up. Statistical analysis showed a borderline correlation between the presence of missense mutations in WDFC and the development of distant metastases during the follow-up (P = 0.05, Fisher's exact text). Among WDFC, missense mutations were also more frequently detected in males (P = 0.13, Fisher's exact text) and tumors >5.5 cm in diameter (P = 0.087, Fisher's exact test).
Correlation of PIK3CA mutations with Ras, BRAF, and P53 status in anaplastic thyroid cancer. All but one of the thyroid carcinomas (69 ATC, 54 WDPC, and 26 WDFC) included in this study had been analyzed for Ras (H-ras, K-ras, and N-Ras) mutations (data partially reported in ref. 20 ) and for BRAF mutations. 7 No statistically significant association was found between Ras or BRAF oncogenic activation and PIK3CA mutations in ATC. Twenty-eight percent of the ATC wild type at PIK3CA (15 of 54) were mutated at Ras and 33% of the ATC mutated at PIK3CA (5 of 15) harbored also a Ras mutation. Likewise, 24% of the ATC wild type at PIK3CA (13 of 54) displayed a BRAF mutation and 40% of the PIK3CA mutated ATC (6 of 15) were concurrently mutated at BRAF. As expected, no ATC was simultaneously mutated at Ras and BRAF, as recognized alternative events in thyroid tumorigenesis (21) . More than half of the ATC wild type at PIK3CA (28 of 54, 52%) were mutated at Ras or at BRAF. Our finding of coexisting PIK3CA/Ras mutations or PIK3CA/BRAF mutations in 11 ATC (73%; Table 2 ) is consistent with previous observations in colon cancer (11) . Sixty-two percent (43 of 69) of the ATC were mutated in at least one of the three genes.
Data not shown of p53 expression, in a TMA with 38 of the ATC studied for PIK3CA mutations (including 10 PIK3CA mutation positive), were available for the correlation with PIK3CA mutations. Seventy-nine percent of the ATC wild type at PIK3CA (22 of 28) exhibited high to moderate levels of p53 immunoreactivity and 70% of the ATC mutated at PIK3CA (7 of 10) showed also distinct levels of p53 staining. Although the statistical analysis did not revealed a significant association between p53 protein expression and PIK3CA mutations, the frequent coexistence of p53 inactivation and PI3K activation in some ATC suggests that the two events may cooperate in thyroid tumorigenesis.
Akt activation in anaplastic thyroid cancer. Correlation with PIK3CA, Ras, BRAF mutations, and proliferative activity. The level of expression and subcellular localization of activated Akt, as a downstream effector of the PI3K gene product, was analyzed in our own TMA of ATC. Total activated Akt was determined using a nonisoform-specific antibody against Akt phosphorylated at Ser 473 . Phospho-Akt staining was considered indicative of Akt activation and, thus, the case recorded as positive, when at least 5% of the cells expressed the phosphorylated form of the protein. Although all of the tissue cores representative of normal thyroid or nodular hyperplasia that were included in the TMA (10 cores from six cases) disclosed focal immunoreactivity, the tumors exhibited a diffuse pattern of staining. The presence of immunoactive Akt in normal thyroid tissue, besides providing an internal control for staining distribution and intensity, may reflect the response of thyroid follicular cells to endogenous physiologic stimuli by thyrotropin and insulin growth factor (22) . Activation of Akt was detected in 38 of 41 ATC (93%). High levels of phospho-Akt were identified in 10 ATC (26%), moderate levels in 19 ATC (50%), and low levels in nine ATC (24%). Of note, in 36 ATC cytoplasmic localization of phospho-Akt was accompanied by different percentages of nuclear reactivity. In two ATC, which were known to originate in a previous tall cell and a follicular variant of papillary carcinoma, the expression of activated Akt was limited to the cytoplasm (see Fig. 3D and P). Figure 3 illustrates phospho-Akt immunoreactivity in several ATC, mutated or not at PIK3CA, as well as its expression in concurrent betterdifferentiated areas within some ATC and three normal thyroids. The correlation between the level of phospho-Akt expression and the mutational status of PIK3CA, Ras, and BRAF genes is summarized in Table 3 . Ten of 16 ATC mutated at PIK3CA were present in the TMA and nine (90%) showed activation of Akt. Two tumors (22%) displayed high levels of phospho-Akt, four tumors (45%) moderate/ distinct levels, and three tumors (33%) low levels. The only ATC mutated at PIK3CA scored negative harbored also a Ras mutation. Seventy-four percent of the ATC featuring immunoactive Akt (26 of 35) were found to be wild type at PIK3CA. Putative alternative molecular mechanisms that may explain Akt activation in those cases are PTEN down-regulation or Ras activation. Indeed, our data indicate that Ras mutations could account for 23% of the ATC that came out wild type at PIK3CA and were Akt positive (6 of 26). Overall, 63% of the ATC showing phospho-Akt immunoreactivity (22 of 35) were mutated either at PIK3CA alone or in association with Ras or BRAF (nine cases), Ras (six cases), or BRAF (seven cases). No evidence of Akt activation was detected in two ATC wild type at PIK3CA.
Although typically thought as a survival factor, Akt is also actively involved in the transduction of proliferation signals by means of the phosphorylation of several downstream substrates (Forkhead transcription factors, GSK3, TSC2, and p27), which play an important role in cell cycle control. Therefore, we sought to determine if Akt activation in ATC was paralleled by increased cellular proliferation rates. In fact, data not shown concerning the proliferative activity of the ATC analyzed for Akt activation were available for the correlation with phospho-Akt staining. Based on the percentage of tumor cell nuclei positive for the proliferation marker Ki67/Mib1, the 41 ATC present in the TMA were divided in three categories (+, z 5% and V 25%; ++, >25% and < 60%; +++, z 60%). One-way ANOVA, with a Bonferroni correction for multiple comparisons across groups, showed a significant association (P < 0.0001) between the mean phospho-Akt score values and all three categories of Ki67/Mib1 immunoreactivity. Likewise, linear regression analysis of phosphoAkt and Ki67/Mib1 values, in all of the 41 ATC included in the TMA, disclosed a highly significant correlation (r = 0.894) between the expression of both proteins (P < 0.0001; SPSS software version 11.0). When considering only the 10 ATC mutated at PIK3CA, which were present in the TMA, no statistical effect was observed beyond the correlation already shown between Akt activation and proliferative activity on 41 ATC. All of the PIK3CA-mutated ATC showing high levels of phospho-Akt (two cases) segregated into the +++ category of Ki67/Mib1 and all of the PIK3CA-mutated ATC featuring low levels of phospho-Akt (three cases) segregated into the + Ki67/Mib1 group. When the four PIK3CA-mutated ATC displaying moderate levels of phospho-Akt were divided according to their proliferation rates, two cases fall within the ++ group and two within the + group. The only PIK3CA-mutated ATC scored as phospho-Akt negative revealed a low Ki67/Mib1 index (+).
Discussion
Several lines of evidence support the hypothesis that PIK3CA mutations in thyroid cancer are functionally important and likely would increase the PI3K activity in the tumors. First, only two silent sequence changes, both in WDFC, were observed among the 21 mutated thyroid cancers. Thus, the ratio of nonsynonymous to synonymous mutations was much higher than the expected 2:1 ratio for nonselected, passenger mutations during tumor progression. Second, the prevalence of missense mutations was much higher than the background mutation frequency of nonfunctional alterations observed in the genome of cancer cells. Third, the residues affected by nonsynonymous amino acid substitutions are highly evolutionary conserved. Fourth, PIK3CA mutations were at or near the amino acid residues previously reported to be targeted by bona fide somatic mutations in different human cancers (11) (12) (13) (14) (15) (16) . Moreover, one of the most frequent alterations found in thyroid carcinomas, H1047R, has been shown to significantly increase the lipid kinase activity in NIH3T3 cells (11) and also to induce the oncogenic transformation of chicken embryo fibroblasts, signaling through the Akt and the mTOR pathways (19) . Very recently, Samuels et al. have reported that H1047R promotes, in human colorectal cancer cells, growth factor-independent cellular proliferation, through Akt-mediated resistance to apoptosis, cell migration, and invasion/metastasis in nude mice (23) .
Our data suggest that PIK3CA mutations may contribute to thyroid cell neoplastic progression. Although further studies are mandatory, the fact that in our series the prevalence of PIK3CA missense mutations was higher in ATC than in well-differentiated thyroid carcinomas seems to support that hypothesis. Moreover, in 18 of 20 ATC cases in which a better differentiated carcinoma component was analyzed, PIK3CA mutations, when present, were restricted to the undifferentiated area. On the other hand, the finding of a E545Q mutation in a highly infiltrative WDPC and the corresponding lymph node metastasis and the finding of a H1047R mutation in a minimally invasive WDFC that gave rise to distant metastases seem also to indicate that PI3K activation plays some role in the spread of thyroid tumor cells both, locally and to distant sites. Accordingly, it has been recently shown that activation of Akt is more pronounced in the invasive regions of thyroid carcinomas and the corresponding lymph node or distant metastases (10) . Further support for a putative role of PIK3CA mutations in the regulation of thyroid cancer cell invasiveness is provided by the correlation observed between PIK3CA mutations or PTEN loss and lymph node metastasis on breast cancer patients (16, 24) . These findings suggest that, in some cases, increased PIP3 production and activation of the PI3K/AKT pathway may enhance invasion of cancer cells. Indeed, PIP3 is involved in the regulation of cell motility (25) . The hypothesis that gain-of-function mutations at PIK3CA (e.g., H1047R) might contribute to the invasive and metastatic phenotypes in naturally occurring tumors is also in agreement with the common occurrence of PIK3CA mutations during the stage of colon tumorigenesis when invasion is initiated (11) . Because it is known that PTEN, which negatively regulates PI3K signaling, is down-regulated in 37% of the well-differentiated thyroid carcinomas and down-regulated or lost in most ATC (3, 7, 8) and constitutively active Ras, which positively regulates PI3K signaling (26, 27) , is found in 50% of the ATC (20) , the activation of PI3K in those tumors might confer and additional advantage for thyroid cancer cells to spread. A phenomenon that could be also mimicked by mutational activation of PIK3CA.
As a readout of PI3K functional activation, we tested Akt phosphorylation in ATC. Despite most of the PIK3CA-mutated ATC were positive for phospho-Akt, our findings show that Akt is generally activated in ATC (93%), regardless of the presence of Figure 3 . Examples of phospo-Akt expression in several ATC, mutated or not at PIK3CA, as well as in concurrent better differentiated carcinoma areas present within some ATC and normal thyroid tissue cores, included in the tissue microarray used to carry out the analysis of Akt activation. A-C, different levels of expression in normal thyroids. In contrast with the tumors, which exhibited a diffuse pattern of staining, the normal thyroids displayed focal immunoreactivity. D, ATC case, wild type at PIK3CA, in which the concurrent well-differentiated follicular variant of papillary carcinoma was negative and the undifferentiated area featured distinct cytoplasmic staining. E-H, PIK3CA mutated ATCs 120, 228, 227, and 223, respectively (see Table 2 ). I, K, M, P, and Q, ATCs wild type at PIK3CA . J, concurrent WDFC component present in the ATC on (I ). L, PDC component present within the ATC on (K ). O and N, concurrent PDC and WDFC areas, present within the ATC on (M ). P, corresponds to one ATC originated in a papillary tall cell carcinoma. Together with that on (D ) are the only two ATC in which phospho-Akt expression was restricted to the cytoplasm. Q, one of the ATC negative for phospho-Akt.
PIK3CA mutations. In addition to oncogenic activation of PI3K, a wide variety of molecular mechanisms may lead to Akt activation on ATC (e.g., Ras activation or PTEN inactivation reported both in >50% of the cases; refs. [3] [4] [5] [6] [7] [8] 20) . Although unfortunately in six of the PIK3CA-mutated ATC could not be assessed Akt activation, our results seem to indicate that multiple signaling pathways (PI3K and Ras), in a separate (Ras in six tumors and PIK3CA in five tumors) and coordinate (Ras plus PIK3CA in four tumors) way, modulate Akt activation. Overall, Ras and/or PIK3CA mutations were observed in 43% of the ATC featuring phospho-Akt immunoreactivity. Of note, 95% of the ATC disclosing activated cytosolic Akt (36 of 38), revealed also different percentages of nuclear reactivity. These findings are in agreement with the fact that the majority of the downstream targets phosphorylated by Akt are located in the cytosol, and some seem to be primarily phosphorylated at the nucleus (28) . Indeed, compartmentalization of activated Akt may be important in determining its cellular effects. Vasko et al. have recently shown that subcellular localization of activated Akt differs between follicular and papillary thyroid cancers. Whereas in follicular cancers phospho-Akt localizes primarily to the nucleus, in papillary cancers, it localizes to the cytoplasm, except for the invasive and metastatic regions where it is expressed in both compartments (10) . It could be hypothesized that phosphorylated Akt is shuttled into the nucleus related to the cell cycle and/or as response to cell division and growth. Although further studies are necessary to determine if differential subcellular compartmentalization of Akt might play some as yet undefined role in delivering mitogenic and survival signals, our results indicate that activation of Akt in ATC is significantly associated with enhanced cellular proliferation. Intriguingly, one of the Akt phosphorylation targets known to play a role in cell cycle control, the cyclin-dependent kinase inhibitor p27, was previously reported to be down-regulated and/or mislocalized to the cytoplasm in a subset of the ATC included in this work (29) . Accordingly, it has been recently shown that p27 is a key target of the growthregulatory activity and cellular proliferation signals exerted by the PTEN/PI3K/AKT pathway in thyroid cancer cells (30) .
The PTEN/PI3K/AKT pathway is known to have a close crosstalk with the Ras/RAF/mitogen-activated protein kinase kinase kinase signaling cascade (26, 27) . Many of our PIK3CA-mutated ATC showed coexisting Ras or BRAF alterations. The presence of double PIK3CA/Ras mutants might indicate that certain PIK3CA mutations (E522K, G1009E, T1031I, and K1041N) are less potent activators of the PI3K pathway. Whatever the explanation for coexisting mutations, the putative cooperation of PI3K signaling and RET/PTC, Ras, or BRAF signaling might have important implications in the behavior of a subset of thyroid carcinomas. Moreover, the frequent coexistence of p53 inactivation and PI3K activation in some ATC might render the cancer cells highly resistant to apoptosis and prone to escape from any restriction of Table 3 . Phospho-AKT expression in ATC: correlation with PIK3CA, Ras and BRAF status growth. The latter association may also contribute to the high genomic instability of ATC, to the clinical presentation of ATC as a rapidly enlarging neck mass as well as to the chemotherapy and radiotherapy resistance of ATC.
In conclusion, oncogenic activation of PIK3CA in thyroid cancer is primarily associated with ATC, which represents the least differentiated histotype and the end point of tumor progression, in the multistage genetic model of thyroid follicular cell tumorigenesis. The study raises the possibility that highly specific smallmolecule inhibitors targeting PI3K or downstream kinases, such as AKT, might have significant therapeutic activity and could be developed into effective anticancer drugs for patients with ATC. Kang et al. have already shown that the inhibitor of TOR, rapamycin, strongly interferes with the transformation of chicken embryo fibroblast induced by the H1047R mutant (19) . Taken together, our data with previously reported alterations in upstream (PTEN, Ras, and RET/PTC; refs. [3] [4] [5] [6] [7] [8] 20) and downstream (Akt and p27; refs. 8, 9, 29, 30) members of the pathway, it would seem that a majority of thyroid cancers have activation of the PTEN/PI3K/AKT pathway, making this pathway extremely attractive for genetargeted therapies. Finally, it would be important to remark that a significant fraction of human cancers share with thyroid cancer the lost of PIP3 homeostasis, due to PTEN inactivation and PIK3CA activation. Because alterations of these two genes tend to be mutually exclusive, it is likely that a big proportion of the most common human neoplasms, such as breast, ovarian, endometrial, colon, prostate cancer, and glioblastomas, have selected for the activation of the PTEN/PI3K/AKT pathway in their pathogenesis, and may therefore benefit from the same small molecule inhibitors.
